Clinical study of bortezomib-based chemotherapy in treatment of newly diagnosed multiple myeloma

Objective To observe the clinical efficacy and adverse effects of bortezomib in treatment of newly diagnosed multiple myeloma(MM).Methods Fifteen MM patients underwent bortezomib-based chemotherapy treatment in Zhongshan Hospital,Sun Yat-sen University.Initial efficacy was evaluated according to the criteria of the CHINA Group for Multiple Myeloma.Toxic reactions were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events(NCI-CTCAE,version 3.0).Results The median follow-up time was 16 months.After receiving different treatment courses,8 cases obtained complete remission,2 nearly complete remission,2 partial remission,1 minimal remission,1 no change,1 progressive disease.Clinical response rate of 15 patients was 80.0%.The most common adverse events were gastrointestinal symptoms(60.0%),followed by peripheral neuropathy(66.7%),leucocytopenia(46.7%),thrombocytopenia(55.6%),infection(23.3%).The fewer adverse events were arrhythmia and heart failure.Conclusion Bortezomib-based chemotherapy is accurately effective in the treatment of newly diagnosed MM with fast-acting,higher remission rate,and safe.